Exploratory meta-analysis of 3 placebo-controlled trials (189 adults with advanced cancer and depression): methylphenidate reduced depressive symptoms at about 2 weeks (SMD -0.81); remission risk ratio was non-significant (RR 1.69, P=0.07); adverse events were similar.
Meta-analysisn = 189
Costa et al. Methylphenidate for Depression in Advanced Cancer: Exploratory Meta-Analysis of Randomized Trials